Zkušenosti s používáním bortezomibu (Velcade) v České republice od roku 2004

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Experience with the use of bortezomib (Velcade) in the Czech Republic since 2004
Authors

SANDECKÁ Viera ŠPIČKA Ivan GREGORA Evžen ŠČUDLA Vlastimil MAISNAR Vladimír KREJČÍ Marta STRAUB Jan PAVLÍČEK Petr MINAŘÍK Jiří RADOCHA Jakub ADAM Zdeněk POUR Luděk ZAHRADOVÁ Lenka HÁJEK Roman

Year of publication 2011
Type Article in Periodical
Magazine / Source Onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords bortezomib; multiple myeloma; treatment response
Description Bortezomib (Velcade) is a representative of class of medicines called proteasome inhibitors. This drug represents quite new and unique medical treatment of the patients with multiple myeloma (MM). This article presents a retrospective analysis of effectiveness and adverse effects in patients with multiple myeloma treated at reference centers of CMG in the Czech Republic. A total 424 patients with multiple myeloma treated with bortezomib from June 2004 to June 2010 were evaluated. The median follow-up was 12,4 months. The mean age of patients was 66 year (34,1–86,5) and majority of them were patients with relapsed multiple myeloma. Of the total 424 patients, 205 patients had bortezomib as second line therapy (48,3 %). Assessment of terapeutic response was possible in 83,3 % of treated patients (353/424). Therapeutic response was achieved in 52,7 % (186/353). Among mentioned responses, complete response was obtained in 14,2 % (50/353). The most severe toxicity observed was peripheral neuropathy, grade 3 or higher was developed in 14 % (49/358). There was recorded a thrombocytopenia grade 3 or higher in 28,8 % (103/357), further occurance of infections grade 2 or higher in 33,6 % (121/359) and eventually we could observe increased number of thromboembolic disease as well. Rapid onset of therapeutic responses and high percentage of obtained complete responses are the main reasons of extraordinary clinical benefit of bortezomib. The most of adverse effects are well controllable by means of appropriate prophylactic precautions, short-term interruptions of treatment, followed by adjustments based on the valid recommendations.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.